Johnson & Johnson (NYSE:JNJ) Shares Sold by Private Wealth Advisors LLC

Private Wealth Advisors LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,626 shares of the company’s stock after selling 176 shares during the period. Johnson & Johnson makes up approximately 1.0% of Private Wealth Advisors LLC’s investment portfolio, making the stock its 26th biggest holding. Private Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,449,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Hibernia Wealth Partners LLC purchased a new position in shares of Johnson & Johnson during the third quarter worth $27,000. FNY Investment Advisers LLC purchased a new position in shares of Johnson & Johnson during the third quarter worth $37,000. Tower View Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Creative Capital Management Investments LLC raised its holdings in shares of Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after purchasing an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth $48,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on JNJ shares. Raymond James raised their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Stock Down 0.1 %

JNJ opened at $152.39 on Monday. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The company has a 50-day moving average price of $158.07 and a 200 day moving average price of $156.31. The company has a market cap of $367.23 billion, a PE ratio of 11.03, a price-to-earnings-growth ratio of 2.56 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter in the prior year, the firm earned $2.35 EPS. The company’s revenue for the quarter was down 9.7% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.